Steve Wise (L) and Kurt von Emster
April 11, 2022 06:52 AM EDTUpdated 10:44 AM
Deals

Car­lyle vaults in­to biotech in­vest­ing, buy­ing Abing­worth and launch­ing a new com­pa­ny aimed at piv­otal leaps

John Carroll

Editor & Founder

Car­lyle Group’s glob­al head of health­care Steve Wise is mak­ing a big for­ay in­to the biotech fi­nanc­ing scene. And the pri­vate eq­ui­ty play­er is acute­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

A service from the Financial Times